Clinical Efficacy and Safety of Low-Dose Pemafibrate in Patients With Severe Renal Impairment: A Retrospective Study
- PMID: 38715994
- PMCID: PMC11076059
- DOI: 10.7759/cureus.57777
Clinical Efficacy and Safety of Low-Dose Pemafibrate in Patients With Severe Renal Impairment: A Retrospective Study
Abstract
Background: The management of hypertriglyceridemia in patients with chronic kidney disease (CKD) is important. Pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator with less toxic effects on liver and kidney function than those of other fibrates, has recently been approved for the treatment of patients with an estimated glomerular filtration rate (eGFR) lower than 30 mL/min/1.73 m2. However, the efficacy and safety of pemafibrate in patients with severe renal impairment have not yet been established.
Methods: This single-center, retrospective observational study included 12 outpatients with CKD and hypertriglyceridemia, who were newly started on low-dose pemafibrate (0.1 mg/day) treatment between December 2021 and May 2023 and whose eGFRs were less than 30 mL/min/1.73 m2 at baseline. Blood samples were collected before and at 12 weeks after pemafibrate treatment.
Results: After 12 weeks of treatment, the serum triglyceride level was significantly decreased, whereas the high-density lipoprotein cholesterol level was significantly increased. The serum alanine aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, and uric acid levels were also significantly decreased, without worsening of the eGFR and serum creatinine levels. In the subgroup analysis, there were no significant differences in the changes in clinical parameters regardless of statin use and CKD stage at baseline.
Conclusions: Low-dose pemafibrate administration in patients with severe renal impairment resulted in significant improvements in triglyceride, high-density lipoprotein cholesterol, and serum uric acid levels, and liver function, without adverse events.
Keywords: chronic kidney disease (ckd); hypertriglyceridemia; pemafibrate; severe renal impairment; spparm alpha; statins.
Copyright © 2024, Shima et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
Similar articles
-
Real-world Profile of a Selective Peroxisome Proliferator-activated Receptor α Modulator (SPPARMα) in Japanese Patients with Renal Impairment and Dyslipidemia.Intern Med. 2021 Sep 1;60(17):2741-2748. doi: 10.2169/internalmedicine.6871-20. Epub 2021 Mar 29. Intern Med. 2021. PMID: 33776008 Free PMC article.
-
Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.Curr Atheroscler Rep. 2020 Jan 23;22(1):5. doi: 10.1007/s11883-020-0823-5. Curr Atheroscler Rep. 2020. PMID: 31974794 Free PMC article. Review.
-
Effect of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator (SPPARMα), on urinary protein excretion in IgA nephropathy with hypertriglyceridemia.CEN Case Rep. 2020 May;9(2):141-146. doi: 10.1007/s13730-020-00444-2. Epub 2020 Jan 16. CEN Case Rep. 2020. PMID: 31950425 Free PMC article.
-
Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases.J Atheroscler Thromb. 2019 May 1;26(5):389-402. doi: 10.5551/jat.48918. Epub 2019 Mar 30. J Atheroscler Thromb. 2019. PMID: 30930344 Free PMC article. Review.
-
Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment.Int J Mol Sci. 2019 Feb 6;20(3):706. doi: 10.3390/ijms20030706. Int J Mol Sci. 2019. PMID: 30736366 Free PMC article. Clinical Trial.
References
-
- Lipoprotein metabolism and CKD: overview. Barter P. Clin Exp Nephrol. 2014;18:243–246. - PubMed
-
- Triglycerides and cardiovascular disease. Nordestgaard BG, Varbo A. Lancet. 2014;384:626–635. - PubMed
-
- Fasting and non-fasting triglycerides and risk of ischemic cardiovascular disease in Japanese men and women: the Circulatory Risk in Communities Study (CIRCS) Iso H, Imano H, Yamagishi K, et al. Atherosclerosis. 2014;237:361–368. - PubMed
-
- Plasma triglycerides and HDL-C levels predict the development of diabetic kidney disease in subjects with type 2 diabetes: the AMD Annals Initiative. Russo GT, De Cosmo S, Viazzi F, et al. Diabetes Care. 2016;39:2278–2287. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous